Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)

被引：1

作者：

Bu, Hong ^{[1
]}

Fan, Ying ^{[2
]}

Fan, Zhaoqing ^{[3
]}

Hu, Xichun ^{[4
]}

Li, Man ^{[5
]}

Li, Qiao ^{[2
]}

Liao, Ning ^{[6
]}

Luo, Ting ^{[7
]}

Nie, Jianyun ^{[8
]}

Pan, Yueyin ^{[9
]}

Qi, Xiaowei ^{[10
]}

Shao, Zhimin ^{[11
]}

Song, Guohong ^{[12
]}

Sun, Tao ^{[13
]}

Teng, Yue-e ^{[14
]}

Tong, Zhongsheng ^{[15
]}

Wang, Jiayu ^{[2
]}

Wang, Shusen ^{[16
]}

Wang, Xue ^{[17
]}

Wang, Yongsheng ^{[18
]}

Wang, Zhonghua

Xu, Binghe ^{[19
]}

Xu, Ling ^{[20
]}

Xue, Yan ^{[21
]}

Yang, Wentao ^{[22
]}

Yao, Herui ^{[23
]}

Ying, Jianning ^{[24
]}

Yuan, Peng ^{[17
]}

Zhang, Jian ^{[4
]}

Zhan, Qingyuan ^{[25
]}

Zhang, Yongqiang ^{[26
]}

Zhao, Jiuda ^{[27
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Dept Internal Med,Canc Hosp, Beijing, Peoples R China

[3] Peking Univ Canc Hosp, Ctr Prevent & Treatment Breast Canc, Beijing Inst Canc Res, Beijing, Peoples R China

[4] Fudan Univ, Shanghai Canc Ctr, Dept Oncol, Shanghai, Peoples R China

[5] Second Hosp Dalian Med Univ, Dept Oncol, Dalian, Peoples R China

[6] Guangdong Prov Peoples Hosp, Dept Breast Canc, Ctr Canc, Guangzhou, Peoples R China

[7] Sichuan Univ, West China Hosp, Breast Dis Ctr, Chengdu, Peoples R China

[8] Yunnan Canc Hosp, Dept Breast Canc 3, Kunming, Peoples R China

[9] First Affiliated Hosp USTC, Anhui Prov Hosp, Dept Oncol, Hefei, Peoples R China

[10] Southwest Hosp AMU, Dept Breast & Thyroid Surg, Chongqing, Peoples R China

[11] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China

[12] Peking Univ Canc Hosp, Dept Breast Oncol, Beijing Inst Canc Res, Beijing, Peoples R China

[13] Liaoning Canc Hosp & Inst, Dept Breast Med, Shenyang, Liaoning, Peoples R China

[14] First Hosp China Med Univ, Dept Oncol, Shenyang, Peoples R China

[15] Tianjin Med Univ Canc Inst & Hosp, Dept Breast Med, Tianjin, Peoples R China

[16] Sun Yat Sen Univ, Canc Ctr, Dept Oncol, Guangzhou, Peoples R China

[17] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept VIP Med Serv,Canc Hosp, Beijing, Peoples R China

[18] Shandong Univ, Shandong Prov Canc Hosp, Breast Dis Ctr, Jinan, Shandong, Peoples R China

[19] Chinese Acad Med Sci & Peking Union Med Coll, Dept Clin Trial Ctr, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China

[20] Peking Univ First Hosp, Breast Dis Ctr, Beijing, Peoples R China

[21] Xian Int Med Ctr Hosp, Dept Oncol, Oncol Hosp, Xian, Peoples R China

[22] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China

[23] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou, Peoples R China

[24] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Pathol,Canc Hosp, Beijing, Peoples R China

[25] Harbin Med Univ, Canc Hosp, Dept Oncol, Harbin, Peoples R China

[26] Beijing Hosp, Dept Oncol, Beijing, Peoples R China

[27] Qinghai Univ, Ctr Mastopathy Diag & Treatment, Affiliated Hosp, Xining 810000, Peoples R China

来源：

JOURNAL OF THE NATIONAL CANCER CENTER | 2023年 / 3卷 / 04期

关键词：

Breast cancer; HER2-low; Antibody -drug conjugate; PROGNOSTIC-FACTOR; EXPRESSION; AMPLIFICATION; SOCIETY; SAFETY;

D O I：

10.1016/j.jncc.2023.09.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistochemistry [IHC] 1 + , or IHC2 + /in situ hybridization [ISH]-) breast cancer, HER2-low may become a new subtype of targeted therapy for breast cancer. The expert committee formulated this consensus based on the current clinical studies and clinical medication experience. The currentconsensus is the collaborative work of an interdisciplinary working group, including experts in the fields of pathology and oncology. The purpose of this consensus was to guide the clinical diagnosis and treatment of HER2-low breast cancer, thereby prolonging the overall survival of patients.

引用

页码：266 / 272

页数：7

共 45 条

[1] HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Agostinetto, Elisa
Rediti, Mattia
Fimereli, Danai
Debien, Veronique
Piccart, Martine
Aftimos, Philippe
Sotiriou, Christos
de Azambuja, Evandro
[J]. CANCERS, 2021, 13 (11)
[2] Bardia A, 2022, J CLIN ONCOL, V40
[3] Birner P, 2001, CLIN CANCER RES, V7, P1669
[4] Camp RL, 2003, CANCER RES, V63, P1445
[5] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F.
Paluch-Shimon, S.
Senkus, E.
Curigliano, G.
Aapro, M. S.
Andre, F.
Barrios, C. H.
Bergh, J.
Bhattacharyya, G. S.
Biganzoli, L.
Boyle, F.
Cardoso, M-J
Carey, L. A.
Cortes, J.
El Saghir, N. S.
Elzayat, M.
Eniu, A.
Fallowfield, L.
Francis, P. A.
Gelmon, K.
Gligorov, J.
Haidinger, R.
Harbeck, N.
Hu, X.
Kaufman, B.
Kaur, R.
Kiely, B. E.
Kim, S-B
Lin, N. U.
Mertz, S. A.
Neciosup, S.
Offersen, B., V
Ohno, S.
Pagani, O.
Prat, A.
Penault-Llorca, F.
Rugo, H. S.
Sledge, G. W.
Thomssen, C.
Vorobiof, D. A.
Wiseman, T.
Xu, B.
Norton, L.
Costa, A.
Winer, E. P.
[J]. ANNALS OF ONCOLOGY, 2020, 31 (12) : 1623 - 1649
[6] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F.
Kyriakides, S.
Ohno, S.
Penault-Llorca, F.
Poortmans, P.
Rubio, I. T.
Zackrisson, S.
Senkus, E.
[J]. ANNALS OF ONCOLOGY, 2019, 30 (08) : 1194 - 1220
[7] Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortes, J.
Kim, S. -B
Chung, W. -P
Im, S. -A
Park, Y. H.
Hegg, R.
Kim, M. H.
Tseng, L. -M
Petry, V
Chung, C. -F
Iwata, H.
Hamilton, E.
Curigliano, G.
Xu, B.
Huang, C. -S
Kim, J. H.
Chiu, J. W. Y.
Pedrini, J. L.
Lee, C.
Liu, Y.
Cathcart, J.
Bako, E.
Verma, S.
Hurvitz, S. A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12) : 1143 - 1154
[8] Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9
[9] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Curigliano, G.
Burstein, H. J.
Winer, E. P.
Gnant, M.
Dubsky, P.
Loibl, S.
Colleoni, M.
Regan, M. M.
Piccart-Gebhart, M.
Senn, H. -J.
Thurlimann, B.
Andre, F.
Baselga, J.
Bergh, J.
Bonnefoi, H.
Brucker, S. Y.
Cardoso, F.
Carey, L.
Ciruelos, E.
Cuzick, J.
Denkert, C.
Di Leo, A.
Ejlertsen, B.
Francis, P.
Galimberti, V.
Garber, J.
Gulluoglu, B.
Goodwin, P.
Harbeck, N.
Hayes, D. F.
Huang, C. -S.
Huober, J.
Khaled, H.
Jassem, J.
Jiang, Z.
Karlsson, P.
Morrow, M.
Orecchia, R.
Osborne, K. C.
Pagani, O.
Partridge, A. H.
Pritchard, K.
Ro, J.
Rutgers, E. J. T.
Sedlmayer, F.
Semiglazov, V.
Shao, Z.
Smith, I.
Toi, M.
Tutt, A.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1700 - 1712
[10] Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
Eggemann, Holm
Ignatov, Tanja
Burger, Elke
Kantelhardt, Eva Johanna
Fettke, Franziska
Thomssen, Christoph
Costa, Serban Dan
Ignatov, Atanas
[J]. ENDOCRINE-RELATED CANCER, 2015, 22 (05) : 725 - 733

← 1 2 3 4 5 →